Automatically calculated report
Latest two-week stopped trial updates
This report covers records updated from 18 July 2026 through 31 July 2026. It recalculates from the newest available ingest whenever the site builds.
Terminated, suspended, or withdrawn records in the window.
6.3% classified as efficacy/futility or safety signals.
Thirteen days before the latest ingested update date.
The newest registry update date available in this ingest.
Source-linked records
Notable efficacy and safety updates
These records are selected from the latest window because their stop language is classified as efficacy/futility or safety. Open the trial page before using any item in research or reporting.
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
- Sponsor
- Janssen Research & Development, LLC
- Phase
- Phase II
- Disease area
- Dermatology
- Updated
- 2026-07-31
Terminated: futility criteria met at interim efficacy analysis.
Early Intravenous Hydrocortisone in Sepsis
- Sponsor
- Siriraj Hospital
- Phase
- Unknown
- Disease area
- Infectious Disease
- Updated
- 2026-07-28
The study was terminated early on December 25, 2025, following the Data and Safety Monitoring Board (DSMB) recommendation due to preliminary evidence of futility.
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
- Sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase II
- Disease area
- Oncology
- Updated
- 2026-07-27
This was a Simon two stage design trial that terminated after the first stage due to lack of response.
Ketamine HCl Prolonged Release Oral Tablets for CRPS
- Sponsor
- University of Southern California
- Phase
- Phase II
- Disease area
- Other
- Updated
- 2026-07-27
Difficulty clearing through the FDA
MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Sponsor
- City of Hope Medical Center
- Phase
- Phase I
- Disease area
- Oncology
- Updated
- 2026-07-24
Pending Interim Analysis
Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
- Sponsor
- University of Colorado, Denver
- Phase
- Phase II
- Disease area
- Oncology
- Updated
- 2026-07-22
Accrual was terminated due to safety concerns
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Phase
- Phase III
- Disease area
- Cardiovascular
- Updated
- 2026-07-22
The ALXN1210-CSA-AKI-318 trial was discontinued on 29-Apr-2026 due to lack of efficacy in this overall study universe / patient population.
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
- Sponsor
- Shionogi
- Phase
- Phase III
- Disease area
- Neurology
- Updated
- 2026-07-20
Futility was met.
Status mix
- TERMINATED
- 77
- SUSPENDED
- 38
- WITHDRAWN
- 12
Stop-reason mix
- OPERATIONAL
- 67
- OTHER/UNKNOWN
- 51
- EFFICACY/FUTILITY
- 6
- SAFETY
- 2
- REGULATORY
- 1
Largest disease areas
- Oncology
- 68
- Other
- 20
- Cardiovascular
- 8
- Gastroenterology & Hepatology
- 8
- Neurology
- 5
- Immunology & Autoimmune
- 4
Largest sponsor counts
- National Cancer Institute (NCI)
- 16
- M.D. Anderson Cancer Center
- 11
- Boehringer Ingelheim
- 3
- National Institute of Allergy and Infectious Diseases (NIAID)
- 3
- Shanghai Junshi Bioscience Co., Ltd.
- 3
- Washington University School of Medicine
- 3
How to use this report
Use it as a monitoring and triage layer. Status alone does not establish drug failure, and short registry explanations can omit endpoint, safety, or strategic context. Verify important findings against ClinicalTrials.gov and related primary documents.